



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|---------------------|
| | | | | Complete If Known: | |
| | | | | Application Number | 10/534650 |
| | | | | Filing Date | May 12, 2005 |
| | | | | First Named Inventor | Darren Mckerrecher |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | Morris, Patricia L. |
| Sheet | 1 | of | 1 | Attorney Docket Number | ASZD-P01-897 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---|-----------------------|---|----------------|
|  | CM1 | McKerrecher et al., "Identification of Orally Bioavailable Small Molecule Activators of Glucokinase," 12th SCI-RSC Medicinal Chemistry Symposium, Cambridge, UK, 7-10 September 2003 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 10/24/06 |
|--------------------|---|-----------------|----------|





PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|--------------|
| Sheet | 1 | of | 3 | Attorney Docket Number | ASZD-P01-897 |
|-------|---|----|---|------------------------|--------------|

Complete If Known

| | |
|----------------------|--------------------|
| Application Number | 10/534650 |
| Filing Date | May 12, 2005 |
| First Named Inventor | Darren McKerrecher |
| Art Unit | 1615 |
| Examiner Name | Not Yet Assigned |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | MM-DD-YYYY | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| DR | BA | WO-00/58293-A1 | 10-05-2000 | F. Hoffmann-La Roche AG | | |
| | BB | WO-01/20327-A1 | 03-22-2001 | AstraZeneca AB | | |
| | BC | WO-01/44216-A1 | 06-21-2001 | F. Hoffmann-La Roche AG | | |
| | BD | WO-01/83465-A2 | 11-08-2001 | F. Hoffmann-La Roche AG | | |
| | BE | WO-01/83478-A2 | 11-08-2001 | F. Hoffmann-La Roche AG | | |
| | BF | WO-01/85706-A1 | 11-15-2001 | F. Hoffmann-La Roche AG | | |
| | BG | WO-01/85707-A1 | 11-15-2001 | F. Hoffmann-La Roche AG | | |
| | BH | WO-02/08209-A1 | 01-31-2002 | F. Hoffmann-La Roche AG | | |
| | BI | WO-02/14312-A1 | 02-21-2002 | F. Hoffmann-La Roche AG | | |
| | BJ | WO-02/46173-A1 | 06-13-2002 | F. Hoffmann-La Roche AG | | |
| | BK | WO-02/48106-A2 | 06-20-2002 | F. Hoffmann-La Roche AG | | |
| | BL | WO-03/000262-A1 | 01-03-2003 | AstraZeneca AB | | |
| | BM | WO-03/000267-A1 | 01-03-2003 | AstraZeneca AB | | |
| | BN | WO-03/015774-A1 | 02-27-2003 | AstraZeneca AB | | |
| | BO | WO-03/022856-A1 | 03-20-2003 | Pharmacia & Upjohn Company | | |
| | BP | WO-03/047626-A1 | 06-12-2003 | Novo Nordisk A/S | | |
| | BQ | WO-03/055482-A1 | 07-10-2003 | Novo Nordisk A/S | | |
| | BR | WO-03/080585-A1 | 10-02-2003 | Banyu Pharmaceutical Co., Ltd. | | |
| | BS | WO-03/095438-A1 | 11-20-2003 | F. Hoffmann-La Roche AG | | |
| | BT | WO-03/097824-A1 | 11-27-2003 | Banyu Pharmaceutical Co., Ltd. | | |
| | BU | WO-04/002481-A1 | 01-08-2004 | Novo Nordisk A/S | | |
| | BV | WO-04/045614-A1 | 06-03-2004 | AstraZeneca AB | | |
| | BW | WO-04/046139-A1 | 06-03-2004 | AstraZeneca AB | | |
| | BX | WO-04/050645-A1 | 06-17-2004 | Novartis AG | | |
| | BY | WO-04/052869-A1 | 06-24-2004 | F. Hoffmann-La Roche AG | | |
| | BZ | WO-04/063179-A1 | 07-29-2004 | Eli Lilly and Company | | |
| | BA1 | WO-04/063194-A1 | 07-29-2004 | Eli Lilly and Company | | |
| | BB1 | WO-04/072031-A2 | 08-26-2004 | Osi Pharmaceuticals, Inc. | | |
| | BC1 | WO-04/072066-A1 | 08-26-2004 | Osi Pharmaceuticals, Inc. | | |
| | BD1 | WO-04/076420-A1 | 09-10-2004 | Banyu Pharmaceutical Co., Ltd. | | |
| | BE1 | WO-04/081001-A1 | 09-23-2004 | Banyu Pharmaceutical Co., Ltd. | | |
| | BF1 | WO-05/044801-A1 | 05-19-2005 | AstraZeneca AB | | |
| | BG1 | WO-05/049019-A1 | 06-02-2005 | Novo Nordisk A/S | | |
| | BH1 | WO-05/054200-A1 | 06-16-2005 | AstraZeneca AB | | |
| | BI1 | WO-05/054233-A1 | 06-16-2005 | AstraZeneca AB | | |
| | BJ1 | WO-05/056530-A1 | 06-23-2005 | AstraZeneca AB | | |

| | | | |
|--------------------|---|-----------------|----------|
| Examiner Signature |  | Date Considered | 10/27/06 |
|--------------------|---|-----------------|----------|

| | | | | | |
|---------------------------------|---|----|---|--------------------------|--------------------|
| Substitute for form 1448A/B/PTO | | | | Complete If Known | |
| | | | | Application Number | 10/534650 |
| | | | | Filing Date | May 12, 2005 |
| | | | | First Named Inventor | Darren McKerrecher |
| | | | | Art Unit | 1615 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 3 | Attorney Docket Number | ASZD-P01-897 |

| | | | | | | |
|----------|-----|---------------|------------|------------------------|--|--|
| <i>✓</i> | BK1 | EP-1336607-A1 | 08-20-2003 | Novo Nordisk A/S | | |
| <i>✓</i> | BL1 | GB-2385328-A | 08-20-2003 | F. Hoffman-La Roche AG | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|--|-----------------------|--|--|--|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| <i>✓</i> | CA | Alvarez et al., "Expression of the Glucagon-Like Peptide-1 Receptor Gene in Rat Brain," Journal of Neurochemistry 66(3):920-927 (1996) | | | | |
| <i>✓</i> | CB | Alvarez et al., "Evidence that Glucokinase Regulatory Protein is Expressed and Interacts with Glucokinase in Rat Brain," Journal of Neurochemistry 80:45-53 (2002) | | | | |
| <i>✓</i> | CC | Bell et al., "Glucokinase Mutations, Insulin Secretion, and Diabetes Mellitus," Annu. Rev. Physiol. 58:171-186 (1996) | | | | |
| <i>✓</i> | CD | Brocklehurst et al., "Stimulation of Hepatocyte Glucose Metabolism by Novel Small Molecule Glucokinase Activators," Diabetes 53:535-541 (2004) | | | | |
| <i>✓</i> | CE | Caro et al., "Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes," Horm. Metab. Res. 27:19-22 (1995) | | | | |
| <i>✓</i> | CF | Christesen et al., "The Second Activating Glucokinase Mutation (A456V) Implications for Glucose Homeostasis and Diabetes Therapy," Diabetes 51:1240-1246 (2002) | | | | |
| <i>✓</i> | CG | Corbett, "Track 3 - Mastering Medicinal Chemistry: Applying Organic Chemistry to Biological Problems, Success Stories in Medicinal Chemistry," Molecular Medicine Tri-Conference, Moscone West Convention Center, San Francisco California, 3/26/05 - 11:00-11:30 Glucokinase Activators: Discovery of Novel, Orally Active Glucose Lowering Agents, March 24-26, 2004 | | | | |
| <i>✓</i> | CH | DeFronzo, "The Triumvirate: β -Cell, Muscle, Liver - A Collusion Responsible for NIDDM," Diabetes 37:667-687 (1988) | | | | |
| <i>✓</i> | CI | Desai et al., "Phenotypic correction of Diabetic Mice by Adenovirus-Mediated Glucokinase Expression," Diabetes 50:2287-2295 (2001) | | | | |
| <i>✓</i> | CJ | Ferre et al., "Correction of Diabetic Alterations by Glucokinase," Proc. Natl. Acad. Sci. USA 93:7225-7230 (1996) | | | | |
| <i>✓</i> | CK | Froguel et al., "Familial Hyperglycemia Due to Mutations in Glucokinase - Definition of a Subtype of Diabetes Mellitus," The New England Journal of Medicine 328(10):697-702 (1993) | | | | |
| <i>✓</i> | CL | Fujimoto et al., "Administration of D-Glucosamine into the Third Cerebroventricle Induced Feeding Accompanied by Hyperglycemia in Rats," Life Sciences 37(26):2475-2482 (1985) | | | | |
| <i>✓</i> | CM | Glaser et al., "Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation," The New England Journal of Medicine 338(4):226-230 (1998) | | | | |
| <i>✓</i> | CN | Grimsby et al., "Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy," Science 301:370-373 (2003) | | | | |
| <i>✓</i> | CO | Grimsby, "Glucokinase Activators - Potential Treatment for Type 2 Diabetes," Roche - SMI Diabetes London UK pgs. 28-29 (2002) | | | | |
| <i>✓</i> | CP | Kurata et al., "Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat," Metabolism 38(1):46-51 (1989) | | | | |

| | | | |
|--------------------|--------------------------------|-----------------|----------|
| Examiner Signature | <i>✓</i> <i>D. McKerrecher</i> | Date Considered | 10/24/06 |
|--------------------|--------------------------------|-----------------|----------|

| | | | | | |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/B/PTO | | | | <i>Complete If Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/534650 |
| Sheet | 3 | of | 3 | Filing Date | May 12, 2005 |
| | | | | First Named Inventor | Darren McKerrecher |
| | | | | Art Unit | 1615 |
| | | | | Examiner Name | Not Yet Assigned |
| | | | | Attorney Docket Number | ASZD-P01-897 |

| | | | |
|----------|-----|--|--|
| <i>✓</i> | CQ | Kurata et al., "D-Glucose Suppression of Eating After Intra-Third Ventricle Infusion in Rat," <i>Physiology & Behavior</i> 37:615-620 (1986) | |
| <i>✓</i> | CR | Levin, "Glucosensing Neurons do More Than Just Sense Glucose," <i>International Journal of Obesity</i> 25(5):S68-S72 (2001) | |
| | CS | Levin et al., "Differential Effects of Diet and Obesity on High and Low Affinity Sulfonylurea Binding Sites in the Rat Brain," <i>Brain Research</i> 739:293-300 (1996) | |
| | CT | Levin et al., "In vivo and In vitro Regulation of [³ H] Glyburide Binding to Brain Sulfonylurea Receptors in Obesity-Prone and Resistant Rats by Glucose," <i>Brain Research</i> 776:146-153 (1997) | |
| | CU | Levin et al., "Brain Glucose Sensing and body Energy Homeostasis: Role in Obesity and Diabetes," <i>A. J. of Physiology</i> 276:R1223-R1231 (1999) | |
| | CV | Levin et al., "Reduced Glucose-Induced Neuronal Activation in the Hypothalamus of Diet-Induced Obese Rats," <i>Brain Research</i> 808:317-319 (1998) | |
| | CW | Lynch et al., "Localization of Glucokinase Gene Expression in the Rat Brain," <i>Diabetes</i> 49:693-700 (2000) | |
| | CX | McKerrecher et al., "Discovery, Synthesis and Biological Evaluation of Novel Glucokinase Activators," <i>Bioorganic & Medicinal chemistry Letters</i> 15:2103-2106 (2005) | |
| | CY | Mobbs et al., "Brain Glucose-Sensing Mechanisms: Ubiquitous Silencing by Aglycemia vs. Hypothalamic Neuroendocrine Responses," <i>Am. J. Physiol. Endocrinol. Metab.</i> 281:E649-E654 (2001) | |
| | CZ | Moore et al., "Acute Fructose Administration Improves Oral Glucose Tolerance in Adults with Type 2 Diabetes," <i>Diabetes Care</i> 24(11):1882-1887 (2001) | |
| | CA1 | Printz et al., "Mammalian Glucokinase," <i>Annu. Rev. Nutr.</i> 13:463-496 (1993) | |
| | CB1 | Qian-Cutrone et al., "Glucolipins A and B, Two New Glucokinase Activators Produced by <i>Streptomyces purpurogeniscleroticus</i> and <i>Nocardia vaccinii</i> ," <i>The Journal of Antibiotics</i> 52(3):245-255 (1999) | |
| | CC1 | Roncero et al., "Functional Glucokinase Isoforms are Expressed in Rat Brain," <i>Journal of Neurochemistry</i> 74(5):1848-1857 (2000) | |
| | CD1 | Rowe et al., "Potassium Channel Dysfunction in Hypothalamic Glucose-Receptive Neurons of Obese Zucker Rats," <i>Journal of Physiology</i> 497(2):365-377 (1996) | |
| | CE1 | Schuit et al., "Perspectives in Diabetes - Glucose Sensing in Pancreatic β -Cells - A Model for the Study of Other Glucose-Regulated Cells in Gut, Pancreas, and Hypothalamus," <i>Diabetes</i> 50:1-11 (2001) | |
| | CF1 | Seoane et al., "Glucokinase Overexpression Restores Glucose Utilization and Storage in Cultured Hepatocytes from Male Zucker Diabetic Fatty Rats," <i>The Journal of Biological Chemistry</i> 274(45):31833-31838 (1999) | |
| | CG1 | Shiota et al., "Glucokinase Gene Locus Transgenic Mice are Resistant to the Development of Obesity-Induced Type 2 Diabetes," <i>Diabetes</i> 50:622-629 (2001) | |
| | CH1 | Spanswick et al., "Insulin Activates ATP-Sensitive K ⁺ Channels in Hypothalamic Neurons of Lean, but Not Obese Rats," <i>Nature Neuroscience</i> 3(8):757-758 (2000) | |
| | CI1 | Spanswick et al., "Leptin Inhibits Hypothalamic Neurons by Activation of ATP-Sensitive Potassium Channels," <i>Nature</i> 390:521-525 (1997) | |
| | CJ1 | Velho et al., "Impaired Hepatic Glycogen Synthesis in Glucokinase-Deficient (MODY-2) Subjects," <i>J. Clin. Invest.</i> 98:1755-1761 (1996) | |
| | CK1 | Yang et al., "Hypothalamic Glucose Sensor - Similarities to and Differences from Pancreatic β -Cell Mechanisms," <i>Diabetes</i> 48:1763-1772 (1999) | |
| <i>✓</i> | CL1 | Carroll et al., "Stress, Signalling and Control, Biochemical Society Meeting 679 2-4 July 2003 | |

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|--------------------|-----------------|----------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 10/24/06 |
|--------------------|--------------------|-----------------|----------|

JC05 Rec'd PCT/PTO 12 MAY 2005

10/534650

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---------------------------------|---|----|---|------------------------|--------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| | | | | Application Number | Not Yet Assigned |
| | | | | Filing Date | May 12, 2005 |
| | | | | First Named Inventor | Darren McKerrecher |
| | | | | Art Unit | Not Yet Assigned |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | ASZD-P01-897 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | | |
| <i>MM</i> | BA | WO-01/44216 | 06-21-2001 | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | ² |
| | CA | Search Report for PCT/GB2003/004919 (2/26/04) | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|----------------|-----------------|----------|
| Examiner Signature | <i>BBH/Min</i> | Date Considered | 10/24/06 |
|--------------------|----------------|-----------------|----------|